Synthetic pineal-derived tetrapeptide bioregulator

Epitalon

aka Epithalon · Epithalone · AEDG · Ala-Glu-Asp-Gly

Evidence grade
Grade C: Preliminary human data
for longevity, telomeres and sleep
User score too few reports (8) needs ≥ 10 reports
US FDA Not approved checked 2026-11-13
WADA 2026 Likely prohibited (S0) by class rule · checked 2026-11-13
EU No EMA approval found; this does not establish the position of every national authority. · checked 2026-11-13

Goals: Sleep · Longevity Compare with another peptide →

User reports

approximate — combined from two independent Reddit reads

Men 45–60

0 men aged 45–60

No reports in this group yet.

All men

0 men

No reports in this group yet.

Everyone

8 people

small sample · n = 8

Outcome unclear 4 of 8 · positive 2 of 8 · mixed 1 of 8 · no effect 1 of 8

Benefits sleep 2 of 8 · energy 1 of 8 · focus / cognition 1 of 8 · mood / anxiety 1 of 8 · other 1 of 8

Side effects insomnia 1 of 8 · other 1 of 8 · vivid dreams 1 of 8

Stopped 0 of 8 Used with other compounds 5 of 8

User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.

In their words

  • “The biggest change and noticeable difference has been in my information recall and retention.”

  • “Epitalon helps put me out a night. I wake up 3.5 hours into sleep wide awake.”

  • “Did not notice any effect on sleep (or any effect at all,)”

  • “I noticed the alignment with the circadian rythm in the beginning. I became tired when it got dark and could sleep early. It healed my insomnia.”

  • “I started Epitalon (0.5mg ED) & Pinealon (1mg ED) two weeks ago to improve sleep metrics. I have tracked sleep on my Garmin”

Read summaries and method notes

Read 1. No reporter provided enough information to enter the men-45–60 block; a poster saying they were “approaching 50” was not counted as age-qualified under the supplied rules. One user reported substantially better information recall after a 12-day subcutaneous course, whereas another described an unusual sleep pattern—easy sleep onset followed by waking after about 3.5 hours—combined with high daytime energy and good mood. A third user reported no perceptible sleep or other effect at all. Thus the small sample spans positive, mixed and no-effect outcomes with no consistent acute signature. The evidence is especially vulnerable to expectancy effects because several posters were using Epitalon for longevity endpoints that cannot be judged subjectively over short periods.

Read 2. No man aged 45–60 (a 49-year-old and an "approaching 50" poster were still waiting for delivery). Seven users from 17 threads: 2 positive (circadian alignment, insomnia resolved), 1 mixed, 4 early unclear. Side effects: vivid dreams, feeling "weird" for 3 days on Pinealon/Epitalon. One buyer got a vial of "wet crystals". Five of seven stacked.

Note 1. Subjective longevity claims were not counted as benefits unless a reporter described a concrete experienced effect. 'Approaching 50' was not treated as an age-qualified 45-60 statement.

Note 2. Two posters in the 45-60 range were waiting for their Epitalon and were excluded as prospective.

Each read counted people independently. Overlap between the two reads is estimated from shared threads and removed; counts are approximate. How we count.

Summary

Synthetic tetrapeptide (Ala-Glu-Asp-Gly; AEDG), distinct from the heterogeneous pineal extract epithalamin. Telomerase/telomere, pineal and antioxidant findings are experimental or biomarker observations; improved human longevity, in-body telomere extension and clinical sleep benefit are not established.

Proposed mechanism

The mechanisms below are hypotheses or experimental findings, not established clinical effects or evidence of a human lifespan gain. Review

  1. Telomere maintenance: Telomerase activation/telomere extension have been reported in cultured human cells; a 33.3% clinical increase in treated people is not established. The 2025 external cell study later received a correction replacing three figures. Cell study, correction
  2. Epigenetic regulation: Binds histone tails + promoter regions
  3. Oxidative stress: Normalizes SOD, catalase, glutathione peroxidase
  4. Immune recalibration: Via pineal/neuroendocrine axis
  5. Circadian restoration: Upregulates AANAT → melatonin synthesis

Safety

  • Human adverse effects and long-term safety are insufficiently characterized
  • Injection-related aggregation and impurities may produce immunogenicity
  • FDA identified a theoretical carcinogenic concern from telomerase activation; cancer risk in humans is unknown

From labels, regulators and trials. No signal in small studies ≠ safe.

Evidence C longevity, telomeres and sleep

C stands, weakly. Epitalon itself has been given to humans in small studies (a 40-person randomized night-shift biomarker study; a poorly reported retinitis pigmentosa report), which clears D. All of it comes from one research group, reports biomarkers not outcomes, and the famous mortality study used epithalamin extract, not epitalon. FDA found no trial in insomnia. Nowhere near B.

Human trials · 2

  1. PMID 332803262020Small randomized placebo-controlled biomarker study with reference group; reporting and blinding unclear 75 people

    Female night-shift workers, including 40 with reduced melatonin production randomized to AEDG or placebo and 35 reference participants

    Reported changes in a urinary melatonin metabolite and clock-gene expression; clinical sleep and longevity outcomes were not established. Source

  2. PMID 121952422002Controlled clinical report; randomization and blinding not established 162 people

    Patients with congenital retinitis pigmentosa; sample size reported by a later review, not in the PubMed abstract

    The authors reported improvement, but the design and outcome ascertainment are insufficient to establish efficacy. Source

Bar length = trial size on a log scale.

Dose ranges

Reported ranges from labels and studies, with context. Not a recommendation.

  • clinical trial
    0.5 mg/day sublingually for 20 days, night-shift biomarker study Source
  • clinical trial
    5 micrograms per eye per day by parabulbar injection for 10 days, retinal study as reported in a review Source

Editorial ratings EDITORIAL

Editors’ judgement, 0–5. Opinion, not data; separate from grade and user score.

  • Safety 4 out of 5
  • Sleep 4 out of 5
  • Recovery 3 out of 5
  • Cognitive 3.5 out of 5

Sources

  1. pubmed.ncbi.nlm.nih.gov/33280326/
  2. pubmed.ncbi.nlm.nih.gov/12195242/
  3. hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  4. wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf?embed=
  5. pmc.ncbi.nlm.nih.gov/articles/PMC13664938/
  6. fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-c
  7. fda.gov/media/193774/download
  8. fda.gov/media/193345/download
  9. govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm
  10. accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=312010
  11. pubmed.ncbi.nlm.nih.gov/40908429/
  12. pubmed.ncbi.nlm.nih.gov/14523363/
  13. pmc.ncbi.nlm.nih.gov/articles/PMC11943447/
  14. pubmed.ncbi.nlm.nih.gov/41240216/
  15. pmc.ncbi.nlm.nih.gov/articles/PMC12411320/
  16. pmc.ncbi.nlm.nih.gov/articles/PMC12619744/

Reddit threads read · 9

5 further sources on commercial or non-primary hosts not listed.

Research checked 2026-11-13.